Table of contents

  1. Joern Krause, Ronald Schmidt
  2. Henning H. Blume
  3. Zheng Lu, Rüdiger Kaspera, Yoichi Naritomi, Tianli Wang
  4. Tanja Eisenblaetter, Lenore Teichert, Ronald Burnette, Paul Hutson
  5. Teodora Handjieva-Darlenska
  6. Evelyn Breitweg-Lehmann, Birgit Liebscher, Carolin Bendadani
  7. Gerd Bode, Petra Starck-Lantova
  8. Anthony G Fenech, Vanessa Petroni Magri
  9. Rainer Heissing, Anne-Ruth van Troostenburg
  10. Lorraine M. Rusch, Clayton Dehn
  11. M. Nikolova, R. Slavchov, G. Nikolova
  12. Federico Goodsaid, Felix Frueh, Michael E. Burczynski
  13. Lynne Hughes, Marie Trad, Stacey Boyer, Deborah Lee, Wei Yin
  14. Liora Bik, Hok Bing Thio
  15. Petar Nikolov, Georgi Banishki, Milena Nikolova-Vlahova
  16. Gulam Mohammed Husain, Mohammad Ahmed Khan, Mohd Urooj, Munawwar Husain Kazmi
  17. Smita Bhuyan, Sebastian Felgner, Dino Kocijancic, Vinay Pawar
  18. Jörg Schüttrumpf, Matthias Germer
  19. Pieter Siebenga, Pieter Okkerse, Guido van Amerongen, Robert Jan Doll, Alex Mentink, Justin Hay et al.
  20. Guy Montay, Jochen Maas, Roland Wesch
  21. Steven G. Woolfrey, James Gilmour Morrison
  22. Yichao Yu, Diether Rüppel, Willi Weber, Hartmut Derendorf
  23. Daniel F. B. Wright, Chihiro Hasegawa, Hesham S. Al-Sallami

About this book


DDrug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined.

As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation document. The methods to detect drug targets are described in the first volume of this series "Pharmacological Assays" comprising classical methods as well as new technologies. Before going to man, the most suitable compound has to be selected by pharmacokinetic studies and experiments in toxicology. These preclinical methods are described in the second volume „Safety and Pharmacokinetic Assays". Only then are first studies in human beings allowed. Special rules are established for Phase I studies. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: „Methods in Clinical Pharmacology".

For the 2nd edition, all the existing chapters will be revised and completely updated. A large number of assays were added. New chapters were included, such as pain, addiction, gene therapy, orphan diseases etc. etc. The complete work was new arranged.


Assays drug action drugs clinical pharmacology pharmacodynamics pharmacokinetics

Editors and affiliations

  • Franz J. Hock
    • 1
  • Michael R. Gralinski
    • 2
  1. 1.CorDynamicsDieburgGermany
  2. 2.CorDynamicsChicagoUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Switzerland AG 2020
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Reference Module Biomedical and Life Sciences
  • Online ISBN 978-3-319-56637-5
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods